EMEND (aprepitant) is a substance P/neurokinin 1 (NK1) receptor antagonist.
Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)
EMEND, in combination with other antiemetic agents, is indicated for the:
Prevention of Postoperative Nausea and Vomiting (PONV)
- prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin
- prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) [see Dosage and Administration].
EMEND is indicated for the prevention of postoperative nausea and vomiting [see Dosage and Administration].
Limitations of Use
EMEND has not been studied for the treatment of established nausea and vomiting.
Chronic continuous administration is not recommended [see Warnings and Precautions].
Media Articles Related to Emend (Aprepitant)
Nausea and Vomiting
Source: MedicineNet Antiemetics Specialty [2016.02.22]
Title: Nausea and Vomiting
Category: Diseases and Conditions
Created: 1/31/2005 12:00:00 AM
Last Editorial Review: 2/22/2016 12:00:00 AM
Naturally occuring symptoms may be mistaken for tamoxifen side effects
Source: Breast Cancer News From Medical News Today [2016.12.12]
Women taking tamoxifen to prevent breast cancer were less likely to continue taking the drug if they suffered nausea and vomiting, according to new data presented at the San Antonio Breast Cancer...
Published Studies Related to Emend (Aprepitant)
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in
children: a randomised, double-blind, phase 3 trial. 
3 trial to examine the safety and efficacy of such treatment in children... INTERPRETATION: Addition of aprepitant to ondansetron with or without
Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and
vomiting following high-dose cisplatin in Chinese patients: a randomized,
double-blind, placebo-controlled phase III trial. 
(HEC) in Asian countries... CONCLUSIONS: The addition of aprepitant to standard antiemetic treatment regimens
Efficacy of aprepitant among patients aged 65 and over receiving moderately to
highly emetogenic chemotherapy: a meta-analysis of unpublished data from
previously published studies. 
analyses from four previously published studies... CONCLUSION: We conclude that for both the under 65years and the age 65 and over
Prevention of nausea and vomiting associated with stem cell transplant: results
of a prospective, randomized trial of aprepitant used with highly emetogenic
preparative regimens. 
Uncontrolled delayed nausea and vomiting remains a problem after high-dose
preparative regimens used for autologous and allogeneic hematopoietic stem cell
transplants. Recently, aprepitant was approved for highly and moderately
emetogenic chemotherapy, and, in particular, is effective for decreasing delayed
Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal
oxycodone in prescription opioid abusers. 
Pre-clinical studies suggest that the neurokinin-1 (NK1) receptor may modulate
the response to opioids, with NK(1) inactivation leading to decreased opioid
reinforcement, tolerance and withdrawal...
Clinical Trials Related to Emend (Aprepitant)
Re-examination Study of EMEND (Aprepitant) (MK-0869-184) [Completed]
This survey is conducted for preparing application materials for re-examination under the
Pharmaceutical Affairs Laws and its Enforcement Regulation. Its aim is to reconfirm the
clinical usefulness of EMEMD (aprepitant) through collecting the safety information
according to the Re-examination Regulation for New Drugs.
Efficacy of Aprepitant (Emend´┐Ż) in Children [Recruiting]
The purpose of this study is to find out whether or not adding aprepitant(Emend«) to the
standard therapy will help children who receive chemotherapy to have less nausea and
Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy [Not yet recruiting]
This study evaluates the addition of fosaprepitant to currently available antiemtic
treatments of carboplatin chemotherapy-induced nausea and vomiting in advanced non-small
cell lung cancer patients. Half of the patients will receive fosaprepitant in their first
chemotherapy cycle, and a placebo on their second chemotherapy cycle. The other half of the
patients will begin their first chemotherapy cycle.
Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects [Recruiting]
This is an open-label, single arm, phase I study to determine the safety, PK characteristics
and anti-inflammatory effects of the NK-R1 coadministered with ritonavir-containing
antiretroviral therapy in individuals with well-controlled viral replication.
Our hypothesis is that Aprepitant will be safe, well tolerated, and will have
anti-inflammatory properties when administered concomitantly with the protease inhibitor
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134) [Terminated]
This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for
the prevention of chemotherapy-induced nausea and vomiting in pediatric participants from 0
months to 17 years of age.
Reports of Suspected Emend (Aprepitant) Side Effects
Drug Interaction (16),
Renal Failure Acute (14),
Septic Shock (9), more >>